Glaucoma: What Every Patient Should Know: A  Guide from Dr. Harry Quigley
Dr. Quigley was born in St. Louis and is a graduate of Harvard College and Johns Hopkins Medical School. After ophthalmic residency at the Wilmer Institute, he did a fellowship at the Bascom Palmer Eye Institute, Miami. He became the A. Edward Maumenee Professor of Ophthalmology in 1994, directing both the Glaucoma Center of Excellence and the Dana Center for Preventive Ophthalmology at Wilmer. He was a founding member of the American Glaucoma Society. He was elected to 5 year terms as chief executive officer of the Association for Research in Vision and Ophthalmology (ARVO) and Editor-in-Chief of Investigative Ophthalmology and Visual Science.       He has published over 350 peer-reviewed articles, and his reports are the most cited in the ophthalmic literature over the last 30 years (Archives of Ophthalmology, 2007). He has been honored with the Friedenwald Award by ARVO, the Doyne Medal by the Oxford Ophthalmological Congress, the Leslie Dana Medal by the St. Louis Society for the Blind, awards from the European Society of Ophthalmology (Prix Jules Francois), Ophthalmological Society of Scotland (Mackenzie Medal), Australian Society of Ophthalmology (Gregg Medal), Irish Ophthalmological Society (Mooney Medal), and the New York Academy of Sciences (Lewis Rudin Prize). He has given 35 named lectures, including the 66th Edward Jackson Lecture (American Academy of Ophthalmology).      Dr. Quigley has trained 55 glaucoma clinician--scientists who practice in the U.S. and worldwide. His research has improved the early diagnosis of glaucoma and has developed instruments and techniques to identify glaucoma damage better. His investigations demonstrated the degree of glaucoma damage that precedes present detection methods. He was the first to report on long-term success with laser iridotomy. His suturing technique for trabeculectomy has been widely adopted.       He has participated in pioneering studies of the epidemiology, morbidity and progression rate of glaucoma and other eye disease in American, African, Asian, and Hispanic populations, serving as a consultant to the World Health Organization. He conceptualized new roles for iris and choroidal volume change as risk factors in angle closure glaucoma.  In the laboratory, he has demonstrated successful gene therapy to protect retinal ganglion cells from experimental glaucoma, and developed glaucoma models in monkeys, rats and mice.